NCT00001259View on ClinicalTrials.gov

A Treatment Study for Premenstrual Syndrome (PMS)

PHASE1CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

August 11, 1992

Primary Completion Date

February 6, 2020

Study Completion Date

February 6, 2020

Conditions
Premenstrual SyndromeMenstruation Disturbances
Interventions
DRUG

Leuprolide

Eight to 12 weeks of GnRH agonist, Leuprolide Acetate 3.75 mg given intramuscularly monthly

DRUG

Estradiol Patches

Transdermal Estradiol, 100mcg/day by skin patch

DRUG

Progesterone

Progesterone suppository, 200mg vaginally twice/day

DRUG

Placebo patch

Placebo by skin patch

DRUG

Placebo injection

Placebo given intramuscularly monthly

DRUG

Placebo suppository

Placebo vaginal suppository

Trial Locations (1)

20892

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

All Listed Sponsors
lead

National Institute of Mental Health (NIMH)

NIH

NCT00001259 - A Treatment Study for Premenstrual Syndrome (PMS) | Biotech Hunter | Biotech Hunter